Breaking News Instant updates and real-time market news.

HPQ

HP Inc.

$21.31

-0.12 (-0.56%)

, CSCO

Cisco

$40.17

1.39 (3.58%)

10:39
02/07/18
02/07
10:39
02/07/18
10:39

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HP Inc. (HPQ) was initiated with a Neutral at Goldman Sachs, while Cisco (CSCO) was initiated with a Buy. 2. Tronox (TROX) initiated with an Outperform at Wells Fargo. 3. Data I/O (DAIO) initiated with a Buy at RF Lafferty. 4. SailPoint Technologies (SAIL) initiated with a Buy at Needham. 5. Aimmune (AIMT) initiated with an Outperform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

HPQ

HP Inc.

$21.31

-0.12 (-0.56%)

CSCO

Cisco

$40.17

1.39 (3.58%)

TROX

Tronox

$20.12

1.225 (6.48%)

DAIO

Data I/O

$10.39

-0.13 (-1.24%)

SAIL

SailPoint Technologies

$16.18

0.52 (3.32%)

AIMT

Aimmune

$35.80

0.48 (1.36%)

  • 13

    Feb

  • 14

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 14

    Mar

  • 29

    Mar

  • 24

    Apr

  • 30

    May

HPQ HP Inc.
$21.31

-0.12 (-0.56%)

02/06/18
GSCO
02/06/18
INITIATION
Target $25
GSCO
Neutral
HP Inc. initiated with a Neutral at Goldman Sachs
Goldman analyst Rod Hall initiated HP Inc. with a Neutral and $25 price target saying valuation appears full.
01/31/18
DBAB
01/31/18
NO CHANGE
Target $15
DBAB
Sell
GE likely to be dropped from Dow 30 index, says Deutsche Bank
General Electric (GE) is likely to be dropped from the Dow Jones Industrial Average after being in the index of 30 companies for over 110 years as an original member since 1896, Deutsche Bank analyst John Inch tells investors in a research note. The chances that GE could be removed from the Dow are increasing as the company continues to face "substantial challenges," the analyst writes. These include "earnings and cash pressure, tough global power generation markets, aggressive downsizing, shrinking its portfolio, management shake-up and SEC investigations," Inch argues. He sees "headline risk" as the most significant risk factor if GE were to be dropped from the Dow, "potentially amplified by GE's high mix of retail investors." Inch notes that the last major Dow shakeup occurred in September 2003, when American Airlines (AAL), Bank of America (BAC) and Hewlett Packard (HPQ) were removed and Goldman Sachs (GS), Nike (NKE) and Verizon (VZ) were added. Inch has a Sell rating on General Electric with a $15 price target. The shares closed yesterday down 33c to $15.95.
02/02/18
MZHO
02/02/18
DOWNGRADE
MZHO
Neutral
HP Inc. downgraded to Neutral on valuation at Mizuho
As previously reported, Mizuho downgraded HP Inc to Neutral from Buy and maintained a $23 price target. Analyst Abhey Lamba said improving fundamentals are reflected in valuation and catalysts are largely played out and sees tough comps on the PSG side and a challenging demand environment in printing.
02/01/18
MZHO
02/01/18
DOWNGRADE
MZHO
Neutral
HP Inc. downgraded to Neutral from Buy at Mizuho
CSCO Cisco
$40.17

1.39 (3.58%)

01/29/18
LOOP
01/29/18
INITIATION
Target $45
LOOP
Hold
Cisco initiated with a Hold at Loop Capital
Loop Capital analyst James Kisner started Cisco Systems with a Hold rating and $45 price target. The analyst prefers to wait for a better entry point following the recent expansion in the company's valuation.
02/06/18
GSCO
02/06/18
INITIATION
Target $48
GSCO
Buy
Cisco initiated with a Buy at Goldman Sachs
Goldman analyst Rod Hall initiated Cisco with a Buy and $48 price target. Hall expects Cisco to be a key beneficiary of capital flows into the tech hardware space led by carrier and network spending and expects cash repatriation to be a significant headwind. In addition, the analyst believes Cisco could make a transformative acquisition to accelerate its transformation to a more software based revenue model.
02/02/18
DBAB
02/02/18
NO CHANGE
Target $52
DBAB
Buy
Deutsche bullish into Cisco quarter, ups target to $52
Deutsche Bank analyst Vijay Bhagavath is bullish into Cisco Systems earnings report on February 14. The analyst raised his price target for the shares to $52 from $48 and keeps a Buy rating on the name. He sees Cisco as a top beneficiary of the rising information technology spending environment and expects multiple expansion from the company's mix shift to software and recurring revenue.
01/31/18
OTRG
01/31/18
NO CHANGE
OTRG
Cisco's channel business remaisn positive, says OTR Global
OTR Global's checks indicate FYQ2 channel sales are at least in line with targets for 19 of 25 partners and switch sales met or exceeded targets for 20 of 24 partners.
TROX Tronox
$20.12

1.225 (6.48%)

12/14/17
12/14/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CBS (CBS) initiated with an Overweight at Stephens. 2. Floor & Decor (FND) initiated with a Buy at Stifel. 3. Tronox (TROX) initiated with an Overweight at Barclays. 4. LivePerson (LPSN) initiated with a Buy at B. Riley FBR. 5. Western Union (WU) assumed with a Sell at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/18
MSCO
01/30/18
INITIATION
Target $21
MSCO
Equal Weight
Tronox initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Vincent Andrews initiated Tronox with an Equal Weight rating and $21 price target, stating that he is constructive on Ti02 prices, but expects more gradual price upside and less frequent increases compared to the past 18 months.
01/30/18
01/30/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altair (ALTR) initiated with a Buy at Berenberg. 2. Chemours (CC), Tronox (TROX) and Venator Materials (VNTR) initiated with an Equal Weight at Morgan Stanley. 3. Oclaro (OCLR), Lumentum (LITE) and Acacia Communications (ACIA) initiated with a Buy at Loop Capital. 4. Rocket Pharmaceuticals (RCKT) initiated with an Outperform at Evercore ISI. 5. U.S. Steel (X) initiated with a Sell at Vertical Group. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/07/18
WELS
02/07/18
INITIATION
Target $28
WELS
Outperform
Tronox initiated with an Outperform at Wells Fargo
Wells Fargo analyst Frank Mitsch started Tronox with an Outperform rating and $28 price target. The analyst has a positive view on the company's acquisition of Cristal and a favorable near-term/sustainable mid-term outlook of TiO2.
DAIO Data I/O
$10.39

-0.13 (-1.24%)

02/07/18
RFLF
02/07/18
INITIATION
Target $15
RFLF
Buy
Data I/O initiated with a Buy at RF Lafferty
RF Lafferty analyst James Anderson initiated Data I/O with a Buy and $15 price target.
11/13/17
LSCM
11/13/17
INITIATION
Target $13
LSCM
Buy
Data I/O initiated with a Buy at Lake Street
Lake Street analyst Jaeson Schmidt started Data I/O with a Buy rating and $13 price target. The company has emerged from its turnaround on a "path of sustained double-digit revenue growth and improving earnings," the analyst contends.
SAIL SailPoint Technologies
$16.18

0.52 (3.32%)

12/12/17
ADAM
12/12/17
INITIATION
Target $15
ADAM
Hold
SailPoint Technologies initiated with a Hold at Canaccord
Canaccord analyst Richard Davis initiated SailPoint Technologies with a Hold and $15 price target citing valuation.
12/12/17
RBCM
12/12/17
INITIATION
Target $18
RBCM
Outperform
SailPoint Technologies initiated with an Outperform at RBC Capital
RBC Capital analyst Matt Hedberg initiated SailPoint Technologies with an Outperform rating and a price target of $18. Hedberg says he is positive on the company "taking share from legacy incumbents within the Identity Governance market, the greenfield opportunity in Data Access Governance, and positive margins with upside."
12/12/17
OPCO
12/12/17
INITIATION
Target $20
OPCO
Outperform
SailPoint Technologies initiated with an Outperform at Oppenheimer
Oppenheimer analyst Shaul Eyal started SailPoint Technologies with an Outperform rating and $20 price target as he believes it is at the forefront of innovation in the IGA market where it holds a ripe opportunity to gain share in the years to come.
02/07/18
NEED
02/07/18
INITIATION
Target $21
NEED
Buy
SailPoint Technologies initiated with a Buy at Needham
Needham analyst Alex Henderson initiated SailPoint Technologies with a Buy rating and a price target of $21, saying the company is a "dominant" player in Identity Governance positioned "at the heart of a spending shift toward better control and command over internal management of access policy". Henderson contends that the company's product offers an improved user experience while also reducing costs by 35% or more.
AIMT Aimmune
$35.80

0.48 (1.36%)

02/07/18
CANT
02/07/18
NO CHANGE
Target $55
CANT
Overweight
Cantor optimistic going into Aimmune Phase III peanut allergy study
Cantor Fitzgerald analyst William Tanner is optimistic on the success of Aimmune Therapeutics' Phase data from the pivotal Palisade clinical trial of AR101, anticipated to occur in February. The company is well positioned to provide the first FDA-approved treatment for peanut hypersensitivity, the most-prevalent food allergy, Tanner tells investors in a research note. He believes Aimmune shares could command up to $84 in a "post-Palisade data acquisition scenario," or up to $93 under certain market scenarios. The analyst keeps an Overweight rating on Aimmune with a $55 price target.
02/07/18
RBCM
02/07/18
INITIATION
Target $55
RBCM
Outperform
Aimmune initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Aimmune with an Outperform rating and a price target of $55. MacKay contends that the company's "phase 3 PALISADE study should succeed based on AR101's phase 2 experience, phase 3 patient characteristics, and comparative trials within the peanut allergy field". He sees AR101 potentially growing the peanut allergy desensitization market, reaching about $1.9B in peak unadjusted global sales.
01/31/18
ROTH
01/31/18
NO CHANGE
Target $75
ROTH
Buy
Aimmune price target raised to $75 from $60 at Roth Capital
Roth Capital analyst Jotin Marango raised his price target for Aimmune to $75 from $60 as he is now more bullish on its value ahead of PALISADE study topline in the next few weeks, full study data on March 4 at AAAAI in Orlando, and potential M&A theses or scenarios that a study win is likely to generate and support. The analyst reiterates a Buy rating on the shares.
01/16/18
CANT
01/16/18
NO CHANGE
Target $55
CANT
Overweight
Aimmune Q1 data should be adequate for approval, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner "strongly" believes Aimmune Therapeutics' Palisade Phase 3 trial data in Q1 will be adequate for FDA approval. AR101 could be an important therapy for treating peanut allergy, Tanner tells investors in a research note following a recent meeting with management. The analyst keeps an Overweight rating on Aimmune shares with a $55 price target.

TODAY'S FREE FLY STORIES

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$0.27

0.0027 (1.02%)

17:43
02/23/18
02/23
17:43
02/23/18
17:43
Hot Stocks
Gabriele Cerrone reports 7.0% stake in ContraVir Pharma, may seek board changes »

The shares of common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

17:41
02/23/18
02/23
17:41
02/23/18
17:41
Periodicals
VW settles U.S. diesel suit just before trial, Reuters reports »

Volkswagen's U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$153.99

3.2 (2.12%)

17:40
02/23/18
02/23
17:40
02/23/18
17:40
Hot Stocks
Breaking Hot Stocks news story on IAC »

Barry Diller reports 8.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SPG

Simon Property

$156.66

2.63 (1.71%)

17:37
02/23/18
02/23
17:37
02/23/18
17:37
Syndicate
Breaking Syndicate news story on Simon Property »

Simon Property files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$28.64

0.99 (3.58%)

17:35
02/23/18
02/23
17:35
02/23/18
17:35
Hot Stocks
Fabrinet director Frank Levinson buys 10,000 shares of company stock »

Frank Levinson, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 12

    Mar

  • 29

    Mar

CASI

Casi Pharmaceuticals

$3.85

0.1 (2.67%)

17:33
02/23/18
02/23
17:33
02/23/18
17:33
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

, TNDM

TNDM

17:31
02/23/18
02/23
17:31
02/23/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Dexcom, TNDM »

DexCom reports 5.6%…

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

TNDM

TNDM

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

  • 04

    Mar

IDXX

Idexx Laboratories

$187.61

3.75 (2.04%)

17:24
02/23/18
02/23
17:24
02/23/18
17:24
Hot Stocks
Idexx Laboratories director sells 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

CYDY

CytoDyn

$0.72

0.02 (2.86%)

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Syndicate
Breaking Syndicate news story on CytoDyn »

CytoDyn files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRUS

Merus

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Merus »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

MSG

Madison Square Garden

$231.97

2.41 (1.05%)

17:19
02/23/18
02/23
17:19
02/23/18
17:19
Hot Stocks
Silver Lake reports 4.9% stake in Madison Square Garden, may seek talks »

Silver Lake are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKL

Markel

$1,121.90

14.9 (1.35%)

17:12
02/23/18
02/23
17:12
02/23/18
17:12
Syndicate
Breaking Syndicate news story on Markel »

Markel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

17:08
02/23/18
02/23
17:08
02/23/18
17:08
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$162.09

2.69 (1.69%)

, MYL

Mylan

$41.45

0.17 (0.41%)

17:04
02/23/18
02/23
17:04
02/23/18
17:04
Periodicals
PTAB denies Allergan's bid to dismiss restasis patent challenge, Bloomberg says »

Allergan's (AGN)…

AGN

Allergan

$162.09

2.69 (1.69%)

MYL

Mylan

$41.45

0.17 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 19

    Mar

  • 25

    Mar

  • 23

    Apr

  • 13

    Nov

SCHW

Charles Schwab

$52.74

0.71 (1.36%)

17:03
02/23/18
02/23
17:03
02/23/18
17:03
Hot Stocks
Charles Schwab appoints Joseph Martinetto as COO of the firm »

On February 22, the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

, BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Kraft Heinz announces retirement of Warren Buffett from Board of Directors »

The Kraft Heinz Company…

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

BUD

AB InBev

$107.25

1.91 (1.81%)

QSR

Restaurant Brands

$59.46

1.02 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

SWX

Southwest Gas

$69.17

1.65 (2.44%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Southwest Gas increases quarterly common stock dividend »

The board for Southwest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

MS

Morgan Stanley

$56.07

1.21 (2.21%)

, AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

16:56
02/23/18
02/23
16:56
02/23/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Applied Optoelectronics »

Morgan Stanley reports…

MS

Morgan Stanley

$56.07

1.21 (2.21%)

AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 12

    Mar

  • 13

    Mar

  • 29

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.